Australia markets open in 2 hours 15 minutes

    -14.20 (-0.20%)

    -0.0072 (-1.11%)
  • ASX 200

    -15.40 (-0.22%)
  • OIL

    -2.07 (-2.28%)
  • GOLD

    -22.50 (-1.21%)
  • Bitcoin AUD

    +1,202.48 (+2.82%)
  • CMC Crypto 200

    -9.25 (-1.53%)

Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

DUBLIN, February 16, 2023--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023 after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.

The conference call will be made available on the Company's website at under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.

To access the call via dial-in, please dial +1 (888) 350-3870 (U.S. and Canada toll free) or +1 (646) 960-0308 (international) five minutes prior to the start time and refer to conference ID number 92750. A replay of the call will be available until March 2, 2023, via dial-in at (800) 770-2030 (U.S. toll free) or +00 1 647 362-9199 (international), Conference ID Number 92750.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at and follow the Company on Twitter @ProthenaCorp.

View source version on



Michael Bachner, Senior Director, Corporate Communications